Regeneron Pharmaceuticals, Inc.’s Stock Price Dips to $558.52, Recording a Sharp 7.47% Drop

Regeneron Pharmaceuticals, Inc. (REGN)

558.52 USD -45.06 (-7.47%) Volume: 1.42M

Regeneron Pharmaceuticals, Inc.’s stock price stands at 558.52 USD, witnessing a significant drop of 7.47% in the recent trading session with a trading volume of 1.42M. With a year-to-date percentage change of -21.59%, REGN’s stock performance reflects a bearish trend.

Latest developments on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Inc. stock faced underperformance on Tuesday compared to its competitors, as Axa S.A. reduced its position in the company. AQR Capital Management LLC also trimmed its stake, while Schonfeld Strategic Advisors LLC bought 18,496 shares. Aspire Growth Partners LLC made a new $421,000 investment, and Voleon Capital Management LP acquired 671 shares. TD Waterhouse Canada Inc. sold some shares, while Mercer Global Advisors Inc. ADV holds $16.66 million in stock holdings. In other news, Regeneron’s drug ‘bundling’ trial with Amgen opened in Delaware, and their drug Lynozyfic received conditional approval in the EU for RRMM. Immuneering also reported a breakthrough in cancer treatment, achieving 13-month survival in a late-stage pancreatic cancer patient. The market for diabetic retinopathy and retinal vein occlusion is set to witness significant growth.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma